pharmaphorum

JUNE 20, 2025

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

Pharma Marketing Network

MAY 1, 2025

Introduction In the rapidly evolving pharmaceutical landscape, staying abreast of emerging pharma trends is crucial for maintaining a competitive edge. As we navigate through 2025, several key developments are reshaping the industry, from technological advancements to regulatory reforms. Disclaimer: This content is not medical advice.

Communication 52

Communication FDA Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 83

Pharmaceutical Companies Pharmaceutical Companies FDA 83

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 89

Pharmaceutical Companies Pharmaceutical Companies FDA 89

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines 66

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 66

The FDA Law Blog

MARCH 18, 2025

Koblitz Integral to the careful balance Congress struck when passing the Hatch-Waxman Amendments, the patent term extension (PTE) is intended to restore patent life that was consumed during regulatory review of an FDA-regulated product. On March 13, 2025, the Federal Circuit ventured into the world of reissued patents and PTE. (

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies FDA 59

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

JUNE 23, 2025

Skip to main content Monday 23 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies FDA 64

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies FDA 95

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies FDA Immunization 59

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies FDA 59

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. A decision from the FDA is possible for later this year, with Lilly currently finalizing an application for fast-track approval.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling FDA 98

Pharma Marketing Network

JANUARY 7, 2025

In 2025, pharma marketing news is filled with innovation, disruption, and opportunities to grow your business. Digital Dominance in Pharma Marketing The digital revolution has officially taken over the pharmaceutical industry, and theres no turning back. A significant focus for regulatory bodies has been on transparency.

HIPAA 52

HIPAA Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

JULY 2, 2025

Skip to main content Wednesday 2 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA Labelling 52

European Pharmaceutical Review

FEBRUARY 27, 2024

Novel biosimilar approval In the same month, the US Food and Drug Administration (FDA) approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference blockbuster drug Stelara (ustekinumab). The post Amgen opens its most advanced manufacturing facility to date appeared first on European Pharmaceutical Review.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies FDA 105

Pharma Marketing Network

MAY 23, 2025

In 2025, artificial intelligence is helping pharmaceutical brands bridge the gap between regulatory precision and meaningful engagement. In 2025, AI is helping medical affairs teams streamline global content review by auto-tagging references, linking claims to citations, and maintaining audit trails.

FDA 64

FDA Documentation Pharmaceutical Companies Pharmaceutical Companies 64

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

European Pharmaceutical Review

AUGUST 1, 2022

The DDiCT initiative aligns with the pharmaceutical company’s broader diversity and inclusion goals for 2020-2025, which aim to address health disparities, clinical trial diversity, supplier diversity, employee giving and workforce representation. Efforts to improve clinical trial diversity are ongoing.

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies FDA 122

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

JULY 1, 2025

billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio. billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio.

Pharmaceutical Companies 66

Pharmaceutical Companies Pharmaceutical Companies Immunization FDA 66

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Packaging FDA 52

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines 71

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 71

Pharmaceutical Technology

JUNE 6, 2025

Robert Barrie June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US health secretary Robert F Kennedy Jr. We are going to make this country the hub of biotechnology innovation,” RFK Jr said during a US Food and Drug Administration (FDA) roundtable on cell and gene therapy on 5 June.

Communication 81

Communication Hospitals Insurance FDA 81

pharmaphorum

JUNE 16, 2025

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies FDA 59

pharmaphorum

JULY 3, 2025

Skip to main content Thursday 3 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

Pharma Marketing Network

APRIL 3, 2025

This article dives deep into how patient marketing has changed, whats driving this transformation, and what strategies are leading the way for 2025 and beyond. Navigating Compliance While personalization and interactivity are powerful, they must align with FDA regulations. FAQs What is patient marketing in pharma?

HIPAA 52

HIPAA Communication Packaging Pharmaceutical Companies 52

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

Pharma Marketing Network

JUNE 5, 2025

In the ever-evolving pharmaceutical industry, advertising plays a crucial role in bridging the gap between pharmaceutical companies and healthcare professionals, as well as consumers. So, what are the strongest forms of traditional advertising in pharma, and why do they still matter in 2025?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA Hospitals 52

pharmaphorum

DECEMBER 21, 2021

However, despite the work still left to be done, there are now a growing number of treatments in the pipeline and 2020 proved to be a remarkable year for orphan drug approvals, with the US FDA approving more orphan designated treatments than non-orphan drugs.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Hospitals FDA 98

European Pharmaceutical Review

MARCH 7, 2024

Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization FDA 52

The Checkup by Singlecare

JANUARY 18, 2024

The patent protection for Nexplanon typically prevents other pharmaceutical companies from creating a generic version until the patent expires. in 2027 and other countries in 2025, when a generic version may be approved. Most insurance companies offer health insurance plans that cover Nexplanon and other birth control methods.

Insurance 52

Insurance Insurance Coverage Packaging Pharmaceutical Companies 52

The Checkup by Singlecare

OCTOBER 27, 2023

How to get Vyzulta without insurance Vyzulta is a brand-name prescription eye drop medication that is approved by the Food and Drug Administration (FDA) to reduce eye pressure in people with open-angle glaucoma or high eye pressure. The earliest date that a generic version could be available is in 2025. Is Vyzulta covered by insurance?

Insurance 52

Insurance Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

APRIL 19, 2022

“In a situation where most of the development of treatments in Korea is mostly centred on cancer and metabolic diseases, I noticed that there weren’t any companies that were focusing on sensory diseases.”. Kim says the Dry Eye Disease market is large and growing, with analysts predicting it will hit $6 billion USD by 2025.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication FDA 52

Pharmacy Times

JUNE 24, 2025

In an interview with Pharmacy Times® , Gabe Hinojosa, PharmD, BCOP, clinical pharmacy specialist oncology/hematology at UT Southwestern, discussed the evolving treatment landscape for multiple myeloma (MM) and presented data from the 2025 American Society of Clinical Oncology Annual Meeting (ASCO).

Compounding Pharmacies 123

Compounding Pharmacies Immunization Hospitals Compounding 123